Travere Therapeutics Reports Quarterly Results for June 30, 2026

What Happened
Travere Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2026 in a press release issued August 4, 2026. The company filed an 8-K (Item 2.02) to disclose those results and attached the press release and related materials as Exhibit 99.1 to the report.

Key Details

• The 8-K was filed August 4, 2026 and references a press release dated August 4, 2026 announcing quarterly financial results for the period ended June 30, 2026.
• Exhibit 99.1 (press release) is included with the filing; the Inline XBRL cover page is provided as Exhibit 104.
• The report was signed by CEO Eric Dube on behalf of Travere Therapeutics.

Why It Matters
This filing signals Travere has released its latest quarterly earnings and related financial information; investors should review the attached press release (Exhibit 99.1) for the company’s reported revenue, earnings, cash position, and operational highlights. The 8-K itself does not repeat the full financial figures, so the exhibit contains the details needed to assess recent performance and update models or watchlists.